<qa>  What is the current FOLFIRINOX regimen limited to?The recently presented FOLFIRINOX regimen shows enhanced activity in metastatic pancreatic cancer patients. This regimen is, however, limited to patients with good performance status ECOG 0-1, no major comorbidity, age 75 years, and bilirubin 1.5 ULN Conroy 2011 6. The majority of pancreatic cancer patients will therefore not be treated with this regimen. 